Back to Search
Start Over
2004-P: Liraglutide Shows Better Weight Loss and Cardiometabolic Benefits than Lorcaserin and Pioglitazone in a Novel Diet-Induced Obese Rat Model
- Source :
- Diabetes. 68
- Publication Year :
- 2019
- Publisher :
- American Diabetes Association, 2019.
-
Abstract
- To evaluate drugs targeting obesity/type 2 diabetes on weight loss and cardiometabolic benefits, and mimic human hyperenergetic nutritional behavior, we set-up a new diet-induced obese (DIO) rat model fed a free choice (FC) diet: control chow (CC) or high fat/cholesterol (HFC) diet, and normal water (NW) or 10% fructose water (FW). After an 8-week FC diet period, rats were treated with vehicle, liraglutide 0.4mg/kg s.c. QD (LIRA, a GLP-1 receptor agonist), lorcaserin 18mg/kg p.o. QD (LORCA, a 5-HT2C receptor agonist) and pioglitazone 10mg/kg p.o. QD (PIO, a PPARgamma agonist) for 5 weeks. FC diet induced high intake of HFC and FW, resulting in significantly higher caloric intake and overweight, as compared with rats fed a CC diet alone. LIRA induced a 12% body weight loss (p In conclusion, LIRA showed superior cardiometabolic benefits than LORCA and PIO in our DIO rat fed a FC diet. This novel model mimicking human overfeeding will be useful to evaluate drugs targeting obesity/type 2 diabetes. Disclosure F. Briand: Employee; Self; Physiogenex. E. Brousseau: Employee; Self; Physiogenex. T. Sulpice: Employee; Self; Physiogenex.
- Subjects :
- Agonist
medicine.medical_specialty
Liraglutide
business.industry
medicine.drug_class
Endocrinology, Diabetes and Metabolism
Type 2 diabetes
Overweight
medicine.disease
Lorcaserin
Endocrinology
Weight loss
Internal medicine
Internal Medicine
medicine
medicine.symptom
business
Pioglitazone
Diet-induced obese
medicine.drug
Subjects
Details
- ISSN :
- 1939327X and 00121797
- Volume :
- 68
- Database :
- OpenAIRE
- Journal :
- Diabetes
- Accession number :
- edsair.doi...........dc62c0db446b07050d5c1b5b20025b55